Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Core Viewpoint - Abeona Therapeutics Inc. has appointed Mohamad Tabrizi as Senior Vice President and Chief Business Officer to enhance corporate strategy and business development efforts [1][2]. Group 1: Appointment and Role - Mohamad Tabrizi will lead the company's corporate strategy and business development functions, focusing on driving operational efficiency [1]. - Tabrizi has extensive experience in strategic planning and business development, which the company aims to leverage for optimizing operations and forming value-creating partnerships [2]. Group 2: Professional Background - Tabrizi previously worked in the venture capital sector as a General Partner and Managing Director at Pandect Bioventures and the Berkeley Catalyst Fund, where he led investment activities and operational roles [2]. - He has a strong track record in corporate development and capital markets, having executed 20 transactions at Nektar Therapeutics and led over 40 transactions as a healthcare investment banker, raising more than $5 billion [3]. Group 3: Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, including its product ZEVASKYN, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa [4]. - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [4].